Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
23 กันยายน 2026
Herbert Smith Freehills Kramer advises Mercuria in $500 million commitment to Project Vault, aimed at strengthening U.S. industrial supply chains
On September 23, 2026, HSF Kramer client Mercuria, one of the world’s largest independent integrated energy and commodities groups, announced a $500 …
22 กันยายน 2026
National Portrait Gallery opens entries for the Herbert Smith Freehills Kramer Portrait Award 2027
Entries of painted portraits to the Herbert Smith Freehills Kramer Portrait Award are welcome from artists aged 18 and over until Tuesday 1 December.
22 กันยายน 2026
Herbert Smith Freehills Kramer advises Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies Munich SE
Herbert Smith Freehills Kramer is pleased to have advised Telix Pharmaceuticals Limited on its transformational merger with ITM Isotope Technologies …